ABOUT US
About Us
Practice Overview
PCK People
Recognition
Careers
Diversity
Pro Bono Services
PCK Events
ABOUT YOU
Start Up
Technology Innovator
Brand Innovator
Professional Services
Volume Patent & Trademark Filer
OTTO
IP STORYTELLERS
SERVICES
TECHNOLOGIES
BLOG
CONTACT
MyPCK
PCKStartup
pharmaceutical patent
Filter by
Categories
Tags
Show all
Article
Confusion
Contract
Copyright
Corporate
Domain Names
Employment
Expungement
Expungement
Grey Marketing
Industrial Designs
Licensing
Obviousness
Opposition
Patent
Patent Infringement
Patent Strategy
PM(NOC)
Procedure
Prosecution
Services
Summary
Trade Secrets
Trade-mark
Use
Validity
3D printing
6.08
abandonment
abstract
abstract theorems
accounting of profits
acquired distinctiveness
actions
actual notice
agreement
airport security
ambiguity
amending
amendment
Amendments
Anticipation
application
application chain
arbitrary
arbitration
Assignment
Australia
bad faith
bill
Bill C-31
Bill C-43
Bill C-8
Bill C-86
biologics
Biotech Patents
book launch
border measures
brand
broadcasting
budget
burden of proof
calculation
call processing
Canada
Canada Gazette
canadian patent law
causal link
cdrp
certificate of supplementary protection
champerty
chemical patent
ciba
CIPO
cira
Claim Construction
Class Actions
college of agents
combination
combination drugs
commissioner
Common General Knowledge
complete code
Confidential Information
confidentiality
confidentiality order
conflict of interest
conflicts
conflicts of interest
confusingly similar
confusion
constitution
constitutional
constitutionality
contract
contributory infringement
Copyright
copyright infringement
copyright test
Costs
counsel
CSP
damages
Data
Data Protection
deadlines
defamation
defences
delay to market entry
delayed market entry
descriptive
design patents
designs
deviation
digital infringement
disclosure
distinctive
distinctive feature
distinctiveness
diversity
division of powers
DNA Patents
domain
domain names
dosage range
Double Patenting
doubtful cases
e-commerce
Early dismissal
errors
essentiality of elements
Ethics
Europe
Evidence
examination quality
examination statistics
expert
expert blinding
expert evidence
Experts
Expungement
extraterritoriality
federal court
federal court of appeal
fee
fees
file wrapper
filing
financial services
foreign issue estoppel
forum selection
fraud
Free World Trust
funding
future infringement
generics
geographical indications
global
Good Faith
Google
government
grace period
grey marketing
Hague
hearsay
hearsay evidence
Honest Contractual Performance
human use
ICSID
Illegality
Improver
Indefiniteness
Inducement
industrial designs
infringement
inherent distinctiveness
injunction
Injunctions
Innovation
insufficiency
insufficient disclosure
intellectual property
intent
Inter Partes Review
interlocutory injunction
Internet
intra vires
invalidated
invalidation
inventor removal
inventorship
IP
IP management
ip regime
IP Strategy
IPO
ISP
IT patent
ITC
Jurisdiction
law
law firm
Legal Retainer
legal test
legislative reform
legitimate interest
license
licensee
Licensing
limitation periods
litigation
litigation evidence
litigation funding agreement
madrid
maintenance
material facts
Methods of Medical Treatment
minister of health
minorities
misleading
monopoly
motion
Motion to dismiss
Motion to strike
NAFTA
new act
no chance of success
non-infringing alternative
non-statutory subject matter
notice of allegation
notice to rectify
novelty
obvious to try
Obviousness
official marks
on-sale bar
Online
ontario
opposition
outsourcing
Overbreadth
overlapping
overpromising
ownership
Ownership & Inventorship
PAB
Passing Off
Patent
patent act
patent agent
Patent Agents
patent appeal board
patent application
patent book
patent eligibility
patent infrigement
patent infringement
patent law
patent litigation
Patent Office
patent ownership
patent protection
patent rules
Patent Strategy
patent term adjustment
patent trolls
Patentable Subject Matter
patented medicines
patented medicines prices review board
patentee
patents
PCT
pharma
pharmaceutical
pharmaceutical patent
pharmaceutical pricing
plain and obvious
PLT
PM(NOC)
PM(NOC) Damages
PMNOC Regulations
PMPRB
posita
price regulation
prices
prior disclosure
prior disclosure defence
priority
priority claim
priority date
Privilege
procedure
Product Specificity
profit
Promise
promise doctrine
proprietor
prosecution
protective order
prothonotaries
provisional patent
Public Servant
Punitive Damages
quantification
ramped-up sales
Records
registration
relevant date for construction
remedies
representation
requisition
responding
Royalties
s. 27
s. 45
s. 53
SCOTUS
second person
Secondary Infringement
secondary meaning
section 101
section 28
Section 45
section 50
Section 52
section 56
section 7
security
selection patents
Services
settlement
skilled person
Software Copyright
Software Patent
software patents
Sound Prediction
specification
springboard profits
SRED
Standard of Review
standing
standing to appeal
Startups
statute of monopolies
statutory subject matter
subject matter
Sufficiency
Summary Judgment
summary trial
supreme court
surname
swiss
tadalafil
TPP
trade secrets
trade-mark
Trade-mark Infringement
Trade-mark Licensing
Trade-mark Use
trade-marks act
trademark
Trademark Act
trademark agent
trademarks
Trademarks use
treaty
UK
United States
unpatentable
untrue material allegation
US
use
useful article
USMCA
USPTO
Utility
validity
variant
Varying records
veterinary use
wenger
women
admin
administrator
Caroline Henrie
Damian Rolfe
Osman Ismaili
PCK
PCK-Reporter
Wendy Low
October 11, 2018
October 11, 2018
What Pharma Patentees Need to Know About Canada’s CSP Regime
Canada’s Certificate of Supplementary Protection Regime – an overview a year into its introduction
